First Horizon Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
$30.1M Buy
162,391
+7,361
+5% +$1.37M 0.78% 37
2025
Q1
$32.5M Sell
155,030
-23,439
-13% -$4.56M 0.91% 30
2024
Q4
$31.7M Buy
178,469
+4,344
+2% +$799K 0.89% 29
2024
Q3
$34.4M Buy
174,125
+2,014
+1% +$376K 0.96% 26
2024
Q2
$29.5M Buy
172,111
+1,304
+0.8% +$216K 0.9% 27
2024
Q1
$31.1M Sell
170,807
-1,034
-0.6% -$178K 0.96% 23
2023
Q4
$26.6M Sell
171,841
-1,256
-0.7% -$183K 0.88% 25
2023
Q3
$25.8M Buy
173,097
+1,312
+0.8% +$193K 0.93% 22
2023
Q2
$23.1M Buy
171,785
+811
+0.5% +$119K 0.8% 31
2023
Q1
$27.2M Buy
170,974
+8,043
+5% +$1.23M 0.97% 19
2022
Q4
$26.3M Sell
162,931
-1,334
-0.8% -$205K 0.97% 20
2022
Q3
$22M Sell
164,265
-3,386
-2% -$486K 0.88% 24
2022
Q2
$25.7M Buy
167,651
+87,643
+110% +$13.4M 0.91% 22
2022
Q1
$13M Sell
80,008
-105,978
-57% -$15.4M 0.71% 34
2021
Q4
$25.2M Buy
185,986
+45
+0% +$5.32K 0.76% 33
2021
Q3
$20.1M Buy
185,941
+36,124
+24% +$4.13M 0.66% 41
2021
Q2
$16.9M Buy
149,817
+4,047
+3% +$456K 0.91% 29
2021
Q1
$15.8M Buy
145,770
+9,720
+7% +$1.04M 0.91% 29
2020
Q4
$14.6M Buy
136,050
+4,475
+3% +$430K 0.98% 26
2020
Q3
$11.5M Buy
131,575
+3,926
+3% +$370K 0.86% 30
2020
Q2
$12.5M Buy
127,649
+34,196
+37% +$3.01M 0.99% 27
2020
Q1
$7.12M Buy
93,453
+5,435
+6% +$463K 0.67% 42
2019
Q4
$7.79M Buy
88,018
+1,749
+2% +$145K 0.57% 49
2019
Q3
$6.53M Buy
86,269
+67,397
+357% +$4.62M 0.51% 53
2019
Q2
$1.37M Buy
18,872
+2,432
+15% +$191K 0.11% 153
2019
Q1
$1.32M Sell
16,440
-2,741
-14% -$224K 0.11% 157
2018
Q4
$1.77M Sell
19,181
-1,883
-9% -$166K 0.16% 136
2018
Q3
$1.99M Buy
21,064
+67
+0.3% +$6.35K 0.16% 137
2018
Q2
$1.94M Buy
20,997
+11,184
+114% +$1.09M 0.16% 136
2018
Q1
$927K Sell
9,813
-441
-4% -$48.4K 0.09% 161
2017
Q4
$993K Buy
10,254
+3,441
+51% +$324K 0.09% 163
2017
Q3
$607K Sell
6,813
-165
-2% -$12.6K 0.06% 189
2017
Q2
$504K Buy
6,978
+3,088
+79% +$208K 0.05% 202
2017
Q1
$254K Sell
3,890
-6,211
-61% -$390K 0.03% 293
2016
Q4
$630K Hold
10,101
0.08% 191
2016
Q3
$630K Buy
10,101
+5,174
+105% +$335K 0.08% 188
2016
Q2
$304K Sell
4,927
-3,225
-40% -$197K 0.04% 243
2016
Q1
$484K Buy
8,152
+1,913
+31% +$107K 0.05% 213
2015
Q4
$369K Buy
6,239
+1,562
+33% +$90K 0.07% 202
2015
Q3
$254K Buy
4,677
+398
+9% +$25.9K 0.04% 248
2015
Q2
$287K Buy
4,279
+136
+3% +$8.88K 0.04% 252
2015
Q1
$242K Buy
4,143
+944
+30% +$57K 0.04% 284
2014
Q4
$209K Sell
3,199
-266
-8% -$16.8K 0.03% 302
2014
Q3
$199K Sell
3,465
-11,850
-77% -$658K 0.03% 304
2014
Q2
$864K Buy
15,315
+1,384
+10% +$72.6K 0.13% 172
2014
Q1
$716K Sell
13,931
-306
-2% -$15.5K 0.1% 179
2013
Q4
$750K Sell
14,237
-55
-0.4% -$2.7K 0.11% 171
2013
Q3
$639K Buy
14,292
+14,176
+12,221% +$628K 0.1% 176
2013
Q2
$5K Buy
+116
New +$5.07K ﹤0.01% 661

Other funds holding ABBV

First Horizon Advisors's ABBV Position: Q2 2025 in Review

First Horizon Advisors increased its AbbVie (ABBV) stake by 4.7% in Q2 2025, buying an estimated $1.37M and bringing the position to 162,391 shares worth $30.1M. The position accounts for 0.78% of the portfolio, ranked #37.

First Horizon Advisors first reported a position in ABBV in Q2 2013 and has held it in 49 quarters since. The position peaked at $34.4M in Q3 2024. 3,781 funds tracked by Wall St. Rank hold ABBV as of Q2 2025.

  • First Horizon Advisors held 162,391 shares of AbbVie worth $30.1M as of Q2 2025.
  • First Horizon Advisors bought 7,361 AbbVie shares in Q2 2025, an estimated $1.37M.
  • AbbVie made up 0.78% of First Horizon Advisors's portfolio in Q2 2025, its #37 holding.
  • First Horizon Advisors first reported a position in AbbVie in Q2 2013 and has held it in 49 quarters since.
  • First Horizon Advisors's AbbVie position peaked at $34.4M in Q3 2024.
  • 3,781 funds tracked by Wall St. Rank held AbbVie as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.